Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Society of Nephrology. Clinical Journal

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2215/CJN.03250410PMID 21088290PMCID PMC3082424
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.

  2011cited by this paper
• Cyclic nucleotide signaling in polycystic kidney disease.

  2010cited by this paper
• Role of sodium intake in the progression of chronic kidney disease.

  2009cited by this paper
• Vascular consequences of dietary salt intake.

  2009cited by this paper
• Copeptin, a Surrogate Marker of Vasopressin, Is Associated With Accelerated Renal Function Decline in Renal Transplant Recipients

  2009cited by this paper
• A comprehensive review on salt and health and current experience of worldwide salt reduction programmes

  2009cited by this paper
• Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I.

  2009cited by this paper
• A case for water in the treatment of polycystic kidney disease.

  2009cited by this paper
• Identification of apolipoproteinA1 reduction in the polycystic kidney by proteomics analysis of the Mxi1‐deficient mouse

  2009cited by this paper
• TGF-β Mediated Epithelial-Mesenchymal Transition in Autosomal Dominant Polycystic Kidney Disease

  2009cited by this paper
• Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets

  2009cited by this paper
• Vasopressin directly regulates cyst growth in polycystic kidney disease.

  2008cited by this paper
• The Yin and Yang of lactosylceramide metabolism: implications in cell function.

  2008cited by this paper
• Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease.

  2008cited by this paper
• Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.

  2007cited by this paper
• The urgent need to reduce sodium consumption.

  2007cited by this paper
• Ouabain binds with high affinity to the Na,K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation.

  2007cited by this paper
• Volume Progression in Polycystic Kidney Disease

  2007cited by this paper
• Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.

  2006cited by this paper
• Volume progression in polycystic kidney disease.

  2006cited by this paper
• Salt intake and depletion increase circulating levels of endogenous ouabain in normal men.

  2006cited by this paper
• Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.

  2006cited by this paper
• Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

  2006cited by this paper
• Plasma Sodium: Ignored and Underestimated

  2005cited by this paper
• Plasma sodium: ignored and underestimated.

  2004cited by this paper
• Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

  2003cited by this paper
• High urine volume and low urine osmolality are risk factors for faster progression of renal disease.

  2003cited by this paper
• Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.

  2003cited by this paper
• Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects.

  2001cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Effects of changes in dietary sodium intake on plasma brain natriuretic peptide levels in patients with autosomal dominant polycystic kidney disease.

  1996cited by this paper
• Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.

  1995cited by this paper
• Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk/cpk) mouse.

  1994cited by this paper
• Hormonal responses to gradual changes in dietary sodium intake in humans.

  1989cited by this paper
• A method for estimating nitrogen intake of patients with chronic renal failure.

  1985cited by this paper

• The many faces of cholesterol in autosomal dominant polycystic kidney disease.

  2026cites this paper
• Development and Validation of a Multivariable Prediction Model for Kidney Failure in Early Autosomal Dominant Polycystic Kidney Disease.

  2025cites this paper
• Unraveling the Genetic Links Between Polycystic Kidney Disease and Hypertension Through ARL13B

  2025cites this paper
• Inactivation of Pkd2 in adult mice results in delayed cyst formation and identifies sex as a major modifier of disease severity.

  2025cites this paper
• Key Aspects in the Nutritional Management of Polycystic Liver Disease Patients

  2025cites this paper
• Renal Prognostic Identification in Patients With Autosomal Dominant Polycystic Kidney Disease by Whole Genome Sequencing: A Prospective, Observational Study

  2025cites this paper
• Brachial-ankle pulse wave velocity predicts liver volume in patients with autosomal dominant polycystic kidney disease

  2025cites this paper
• Rare Complication of Renal Torsion in Autosomal Dominant Polycystic Kidney Disease following an Intraperitoneal Kidney Transplantation

  2025cites this paper
• Navigating Nutrition Therapy for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

  2025cites this paper
• Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan

  2025cites this paper
• KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

  2025cites this paper
• Water intake, baseline biopsy, and graft function after living donor kidney transplantation

  2024cites this paper
• Treatment of Autosomal Dominant Polycystic Kidney Disease.

  2024cites this paper
• A Case of Acquired Cystic Kidney Disease From Chronic Renal Failure Without Dialysis

  2024cites this paper
• Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression

  2024cites this paper
• Potential Add-On Benefits of Dietary Intervention in the Treatment of Autosomal Dominant Polycystic Kidney Disease

  2024influential citation
• Visceral Abdominal Adiposity and Autosomal Dominant Polycystic Kidney Disease Progression: One More Step Toward Identifying Useful Biomarkers and Characterizing the Disease Metabolic Links.

  2024cites this paper
• Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models.

  2024cites this paper
• Is mild dehydration a risk for progression of childhood chronic kidney disease?

  2024cites this paper
• The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan

  2024influential citation
• How Does ADPKD Severity Differ Between Family Members?

  2024cites this paper
• Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers

  2023cites this paper
• Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD—a randomized controlled trial

  2023cites this paper
• Predictors of progression to end-stage renal disease among patients with polycystic kidney disease type 1 in Alexandria Governorate Egypt

  2023cites this paper
• Baseline characteristics of the Korean genetic cohort of inherited cystic kidney disease

  2023cites this paper
• Polycystic Kidney Disease Diet: What Is Known and What Is Safe.

  2023cites this paper
• Sodium Management in Kidney Disease: Old Stories, New Tricks.

  2023cites this paper
• Diet and Polycystic Kidney Disease: Nutrients, Foods, Dietary Patterns, and Implications for Practice.

  2023cites this paper
• PKD1 Mutation Is a Biomarker for Autosomal Dominant Polycystic Kidney Disease

  2023cites this paper
• Diet and Physical Activity in Adult Dominant Polycystic Kidney Disease: A Review of the Literature

  2023cites this paper
• Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study

  2023cites this paper
• Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.

  2023cites this paper
• Biomarkers in Polycystic Kidney Disease: Are We There?

  2023cites this paper
• Drug repurposing in ADPKD.

  2023cites this paper
• The Relationship Between Dietary Intakes and Total Kidney Volume in Patients with Autosomal Dominant Polycystic Kidney Disease Dietary Intake and Polycystic Kidney Volume

  2022cites this paper
• A Systematic Review of Reported Outcomes in ADPKD Studies

  2022cites this paper
• Autosomal dominant polycystic kidney disease in young adults

  2022cites this paper
• Changing the Outcome of a Pediatric Disease: Part II — Current Treatment Options in ADPKD

  2022cites this paper
• The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life

  2022cites this paper
• Increased Body Fat and Organic Acid Anions Production Are Associated with Larger Kidney Size in ADPKD

  2022cites this paper
• Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression

  2022cites this paper
• Urine-to-Plasma Urea Ratio: Disentangling Tubular Concentrating Ability From GFR.

  2022cites this paper
• Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD)

  2021influential citation
• Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease

  2021cites this paper
• The wind of change in the management of autosomal dominant polycystic kidney disease in childhood

  2021cites this paper
• Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease

  2021cites this paper
• Water intake and progression of chronic kidney disease: the CKD-REIN cohort study.

  2021cites this paper
• Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease

  2021cites this paper
• Autosomal Dominant Polycystic Kidney Disease

  2021cites this paper
• The Relationships between Water Intake and Hydration Biomarkers and the Applications for Assessing Adequate Total Water Intake among Young Adults in Hebei, China

  2021cites this paper
• The association of urine osmolality with decreased kidney function and/or albuminuria in the United States

  2021cites this paper
• Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases

  2021cites this paper
• Emerging non-pharmacological interventions in ADPKD: an update on dietary advices for clinical practice

  2021cites this paper
• Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.

  2020influential citation
• Complications of Polycystic Kidney Disease and Relation With Disease Progression: An Observational Retrospective Study

  2020cites this paper
• High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study

  2020cites this paper
• Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease

  2020cites this paper
• Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.

  2020cites this paper
• Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease

  2020cites this paper
• Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

  2019cites this paper
• Recent advances in the clinical management of autosomal dominant polycystic kidney disease

  2019cites this paper
• Salt-deficient diet exacerbates cystogenesis in ARPKD via epithelial sodium channel (ENaC)

  2019cites this paper
• Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course

  2019cites this paper
• Fasting Urinary Osmolality, CKD Progression, and Mortality: A Prospective Observational Study.

  2019cites this paper
• International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people

  2019cites this paper
• Association of Vitamin D Levels With Kidney Volume in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  2019cites this paper
• Improving treatment and imaging in ADPKD

  2019cites this paper
• Dietary Care for ADPKD Patients: Current Status and Future Directions

  2019cites this paper
• [Modern approaches to conservative therapy of polycystic kidney disease].

  2019cites this paper
• Autosomal dominant polycystic kidney disease: updated perspectives

  2019influential citation
• Urine Osmolality and Renal Outcome in Patients with Chronic Kidney Disease: Results from the KNOW-CKD

  2019cites this paper
• TCRM_A_196244 1041..1052

  2019influential citation
• Glucose and Lipid Metabolism Abnormalities among Patients with Autosomal Dominant Polycystic Kidney Disease

  2019cites this paper
• The role of DNA damage as a therapeutic target in autosomal dominant polycystic kidney disease

  2019cites this paper
• Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective

  2018cites this paper
• Clinical Manifestation, Management and Prognosis of Acute Myocardial Infarction in Autosomal Dominant Polycystic Kidney Disease

  2018cites this paper
• Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

  2018cites this paper
• Models for earlier prognosis of renal decline in polycystic kidney disease (PKD) patients

  2018cites this paper
• Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

  2018cites this paper
• Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?

  2017cites this paper
• Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

  2017cites this paper
• New treatment paradigms for ADPKD: moving towards precision medicine

  2017cites this paper
• Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

  2017cites this paper
• Diet and polycystic kidney disease: A pilot intervention study.

  2017cites this paper
• NOS3 gene Glu298Asp polymorphism and severity of disease in patients of ADPKD from North India

  2017cites this paper
• Polycystic Kidney Disease and the Vasopressin Pathway

  2017cites this paper
• Polycystic kidney disease

  2017cites this paper
• University of Groningen Polycystic Kidney Disease and the Vasopressin Pathway

  2017cites this paper
• Kidney Week 2016

  2017cites this paper
• Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

  2017cites this paper
• Polycystic kidney disease

  2017cites this paper
• Experiences and Perspectives of Polycystic Kidney Disease Patients following a Diet of Reduced Osmoles, Protein, and Acid Precursors Supplemented with Water: A Qualitative Study

  2016cites this paper
• ECE1 gene variant shows tendency toward chronic kidney disease advancement among autosomal polycystic kidney disease patients

  2016cites this paper
• Utilidad de una consulta de enfermedades renales hereditarias: un enfoque diferente basado en el árbol genealógico

  2016cites this paper
• Diagnostic Algorithm in the Management of Acute Febrile Abdomen in Patients with Autosomal Dominant Polycystic Kidney Disease

  2016cites this paper
• CRISP 3 PROTOCOL: RENAL IMAGING TO ASSESS PROGRESSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): EXTENSION (CRISP III)

  2016cites this paper
• Clinical Manifestation and Management of ADPKD in Western Countries

  2016cites this paper
• Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016.

  2016cites this paper
• Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

  2016cites this paper
• Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients

  2016cites this paper